November 2013, Vol 2, No 7

← Back to Issue

PMO Proudly Announces Dr Sanjiv S.Agarwala to Join Dr Al Benson as Co-Editor in Chief

Al B.
Benson III, MD

Dear Colleague,

It is with great pleasure that I announce our newly appointed Co-Editor in Chief, Sanjiv S. Agarwala. Dr Agarwala joins me in this position to bring the oncology community the latest advances in our ability to personalize care for patients.

Dr Agarwala is Professor of Medicine at Temple University School of Medicine in Philadelphia and Chief of Oncology & Hematology at St. Luke’s Cancer Center in Bethlehem, Pennsylvania.

Dr Agarwala is an internationally recognized investigator in the field of melanoma and immunotherapy. He has published on a variety of therapeutic approaches to melanoma and has led promising clinical trials of immunotherapy and targeted therapy of melanoma. He received his degree and completed an internship and residency at the Seth G.S. Medical College and King Edward Memorial Hospital in Bombay, India. He also completed residency training in internal medicine and a fellowship in hematology-oncology at the University of Pittsburgh School of Medicine.

We are delighted to work with him at PMO, and it is my pleasure to welcome him in this capacity.


Al B. Benson III, MD



Sanjiv S.
Agarwala, MD
Dear Colleague,

It is my pleasure to write to you as Co-Editor in Chief of PMO alongside Dr Benson. The world of oncology has seen more promise, change, and improvements in the past decade than ever before. The Editors and Staff of PMO are proud to be part of that change by meaningfully disseminating potentially life-changing information to our readership. In my new capacity, I hope to continue this tradition by featuring articles within our pages that provide in-depth information about emerging therapies, various genetic mutations, protein expressions, and other indicators and their implications for treatment in different subsets of patients with cancer.

It is our hope that these pages assist you in providing optimal care for your patients. I look forward to serving you.


Sanjiv S. Agarwala, MD
Uncategorized - December 3, 2013

Personalized Cancer Treatment: Combination Therapies May Be Key to Hitting Tumor Heterogeneity

Combinations of targeted therapies will be key to overcome resistance that occurs in tumor cells that leads to eventual failure of a single targeted agent, said Alex Adjei, MD, PhD, at the second annual Global Biomarkers Consortium conference. “Tumor heterogeneity is the predominant reason for therapeutic failure in cancer,” he [ Read More ]

Uncategorized - December 3, 2013

Understanding Molecular Subtypes Is Basis for Genomic Medicine in Prostate Cancer

Incorporating genomics into the practice of medicine requires demonstration of the ability of biomarkers to impact clinical decision making and ensuring that patients receive the best therapy based on genomic findings. Scott Tomlins, MD, PhD, reviewed efforts to realize genomic medicine into prostate cancer diagnosis and management at the second [ Read More ]